Author:
Wu Han,Jiang Weitao,Pang Ping,Si Wei,Kong Xue,Zhang Xinyue,Xiong Yuting,Wang Chunlei,Zhang Feng,Song Jinglun,Yang Yang,Zeng Linghua,Liu Kuiwu,Jia Yingqiong,Wang Zhuo,Ju Jiaming,Diao Hongtao,Bian Yu,Yang Baofeng
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27(2): 625–643
2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8(1): 30–41
3. González A, Schelbert EB, Diez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 2018; 71(15): 1696–1706
4. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016; 106(1): 62–69
5. Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 2019; 12(4): e005565